Biocon’s arm collaborates with Voluntis to develop, distribute innovative digital therapeutics

21 Jul 2020 Evaluate

Biocon’s step down subsidiary -- Biocon Sdn. Bhd., Malaysia has collaborated with Voluntis to develop and distribute innovative digital therapeutics supporting people with diabetes on biologics therapy. The licensing agreement will make Biocon Sdn. Bhd subsidiary of Biocon Biologics India one of the first insulins companies to offer a U.S. Food and Drug Administration-cleared and CE-marked, highly validated digital therapeutic product, Insulia, to Type 2 diabetes patients, across several markets in the world.

Insulia provides automated insulin dose recommendations enabling people with diabetes to self-manage their condition and healthcare teams to remotely monitor progress. Insulia is the first digital therapeutic with regulatory clearance to provide automated titration recommendations for all types of basal insulins.

Biocon is India’s largest and Asia’s leading Biotechnology Company with a strategic focus on biopharmaceuticals and research services. It is a fully integrated, innovation driven biopharma enterprise offering affordable solutions for chronic diseases to patient's worldwide.

Biocon Share Price

386.65 5.10 (1.34%)
12-Dec-2025 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1794.30
Dr. Reddys Lab 1279.65
Cipla 1517.20
Zydus Lifesciences 929.05
Lupin 2114.10
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×